S1PR5 and myeloid sarcoma: The recent phase-3 EXPAND trial demonstrated that oral administration of siponimod (BAF312), which targets S1P1 and S1P5 (17), attenuates the risk of disability progression in SP-MS, with a major effect in those patients with inflammatory disease (18).